Developing and Acquiring Life-Saving Medical Products - Investor Presentation July 2021 OTC: ODYY
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Developing and Acquiring Life-
Saving Medical Products
Investor Presentation
July 2021
OTC: ODYY
©2021 Odyssey Group International | OTC: ODYY 1
Forward Looking Statements
This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including
statements regarding Odyssey Group International, Inc.’ (“Odyssey Group International, Inc.” or the “Company”) future results of operations and financial
position, including the financial results for the year ended July 31, 2020, financial targets, business strategy, plans and objectives for future operations, are
forward-looking statements. The Company has based these forward-looking statements largely on its current estimates of its financial results and its
current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations,
business strategy, short term and long-term business operations and objectives, and financial needs as of the date of this presentation. These forward-
looking statements are subject to a number of risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in the
Company’s filings with the Securities and Exchange Commission (the “SEC”). Moreover, the Company operates in a very competitive and rapidly changing
environment. New risks emerge from time to time. It is not possible for Company management to predict all risks, nor can the Company assess the impact
of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained
in any forward-looking statements the Company may make. In light of these risks, uncertainties and assumptions, the forward-looking events and
circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in
the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although the Company believes that
the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee that the future results, levels of activity,
performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither the Company nor any
other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Except as required by law, the Company
undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this presentation, to conform these
statements to actual results or to changes in the Company’s expectations. The Company’s filings with the Securities and Exchange Commission are
available to you and you should read the documents the Company has filed with the SEC for more complete information about the Company. You may get
these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov.
©2021 Odyssey Group International | OTC: ODYY 2
About Odyssey Group International
Asset acquisition company focused on unique, life-saving
medical products that offer clinical advantages
Strong leadership team of seasoned pharma and
medical device industry veterans
Multiple products in development with an array of
near-term milestones
Potential to commercialize products as early as 2022
©2021 Odyssey Group International | OTC: ODYY 3
Products in Development
Pharmaceuticals Medical Devices
• PRV-002
• CardioMap
Novel compound for treatment of
Heart monitoring and screening
mTBI (concussion) which currently
device for early detection of
has no FDA approved drug
coronary artery disease
• PRV-001
• Save-A-Life
Novel compound intended to treat
handheld choking rescue device
Niemann-Pick disease; potential
Orphan Drug designation
©2021 Odyssey Group International | OTC: ODYY 4
PRV-002
Novel Compound for Treatment
of Concussion
©2021 Odyssey Group International | OTC: ODYY 5
About Concussion
Concussions, represent a significant unmet medical
75%
need Likelihood of athlete head-
injury recurrence
• > 5 Million per year in the US, 69M worldwide
• Medical costs in the US is $10-15 Billion per
year in US, $400B worldwide
Current standard of care is rest, analgesics for
33%
headache, anti-depressants and ADHD medications Individuals over 65 that fall annually;
50% of deaths are from brain injury
Repeat concussions lead to early dementia and
Chronic Traumatic Encephalopathy
No currently approved FDA drug treatment exists
25x
Frequency of military PTSD
development post-concussion
©2021 Odyssey Group International | OTC: ODYY 6
About PRV-002
• New chemical entity: Proprietary Neurosteroid
• Proven in-vivo efficacy in animal concussion
models through gene amplification of anti-
inflammatories, anti-oxidants and efflux fluid
channels
• Safety margin > 300-fold in animal toxicology
studies
• Nasal administration drives drug into the brain in
minutes
• Potential revenue worldwide over $6B with
significant healthcare savings
©2021 Odyssey Group International | OTC: ODYY 7
Preclinical Results
PRV-002 Significantly PRV-002 Significantly
Improved Neuroscore Improved Memory
Score
Neurobehavioral Battery
Scored sensory motor function Morris Water Maze
based on 4 movement In before and after comparisons
behaviors, rats subjected to of rats after subjected to
concussion model and treated concussion model, rats treated
with PRV-002 outperformed with PRV-002 outperformed
those treated only with vehicle those treated only with vehicle
©2021 Odyssey Group International | OTC: ODYY 8
Sports Advisory Board
March 2021, Odyssey announced the formation of a Sports Advisory
Board
The SAB will
• Kurt Warner – NFL Hall of Fame, NFL MVP, Super Bowl MVP, Super
Bowl Champion
support Odyssey’s
outreach efforts to
• Brett Favre – NFL Hall of Fame Quarterback, Super Bowl
Champion, 3x consecutive MVP
enhance public
awareness of
• Abby Wambach – 2x Olympic gold medalist, World Cup champion,
and winner of the FIFA World Player of the Year traumatic brain
• Mark Rypien – 2x Super Bowl Champion, 1st Canadian quarterback
injuries and
to start in the NFL concussion as well
• David Ross – Current Manager of the Chicago Cubs, 2x World as the need for an
Series Champion catcher FDA approved
• Steve “Mooch” Mariucci – Head coach San Francisco 49er’s from therapy.
1997-2002 and Detroit Lions from 2003-2005, current member of
the NFL’s Player Safety Advisory Committee
©2021 Odyssey Group International | OTC: ODYY 9Scientific Advisory Board
James P. Kelly, MA, MD, FAAN, – Dr. Kelly is the Executive Director of the Marcus Institute for
Brain Health (MIBH) and Professor of Neurology at the University of Colorado Anschutz Medical Campus
in Aurora, CO. He is National Director of the Gary Sinise Foundation Avalon Network TBI Medical
Programs for which the MIBH serves as the clinical coordinating center. His immediate past position was
Director of the National Intrepid Center of Excellence (NICoE) at Walter Reed National Military Medical
Center in Bethesda, MD.
Dallas C. Hack, MD, MPH, FACMPH, COL, US Army- COL(R) Hack then served as the Command
Surgeon for the US Army Central Command-Kuwait from 2001 to 2002, where he directed medical care
for the US military in Kuwait, Saudi Arabia, and Qatar. He also served as Deputy Commander for Clinical
Services for 3rd MEDCOM, assisting with planning medical support for Operation Enduring Freedom and
providing clinical oversight over medical operations in Afghanistan and Pakistan.
Dr Bob Arnot - Dr. Arnot is the former Chief Medical Correspondent at Dateline NBC, The Today
Show, NBC Nightly News, CBS News, CBS Evening News, 48 Hours, and CBS This Morning. He is a New
York Times best selling author. Dr. Arnot is the current Dean of Advanced Technology and International
Education at the New York Film Academy. He previously served on the board for Pine Manor College and
Harvard affiliated Joslin Diabetes centers Board of Incorporators and was the National Medical Director
of National Emergency Services.
©2021 Odyssey Group International | OTC: ODYY 10Timeline and Milestones
PRV-002 2Q21 3Q21 4Q21 1Q22
Complete Device prototype
Finalize Nanoparticle Formulation
Initiate Phase 1A Trial
Complete Phase 1A Trial
Initiate Phase 1B Trial
Complete Phase 1B Trial
Meet with FDA on Phase 2 Trial
©2021 Odyssey Group International | OTC: ODYY 11
All timing pending availability of capital resources for each programPRV-001
Novel compound for Treatment
of Niemann-Pick type C Disease
©2021 Odyssey Group International | OTC: ODYY 12Niemann-Pick type C Disease
A rare neurodegenerative-lysosomal storage disorder
• Cholesterol build-up
5-20 years
• Microglia-activated Average NPC Patient Life
inflammation Expectancy
• Ataxia, Dysphagia and
Cognitive Decline
Drug Mechanism of Action 1 in 150,000
• Stimulates the Pregnane X Receptor Estimated US Prevalence
• Increases export of piled-up cholesterol through
the P-Glycoprotein channel
• Activates CD55 which reduces microglial-activated
5x
cerebellar inflammation Higher incidence in Middle
Eastern populations
©2021 Odyssey Group International | OTC: ODYY 13Orphan Drug Candidate
We anticipate receiving Orphan Drug designation from the FDA
for PRV-001
• NPC is considered an orphan disease by the FDA
• Orphan Drug status accelerates pathway to FDA approval
• Successful development of PRV-001 may earn a Pediatric Disease Priority Review
Voucher
If approved, Orphan Drug designation results in market exclusivity for 7 years
©2021 Odyssey Group International | OTC: ODYY 14CardioMap System
Heart Monitoring and Screening Device
In development, not commercially available 15
©2021 Odyssey Group International | OTC: ODYYCardioMap System
Small, portable device for early detection
of heart disease more effective than
traditional imaging services
Fast regulatory pathway via 510(k) – small
study to show equivalence to legacy EKG
Highly profitable razor-razor blade model
with recurring cloud-based service
Multiple end markets: Hospitals,
Doctors’ offices, Rehabilitation Centers,
Sports Medicine Markets
©2021 Odyssey Group International | OTC: ODYY 16Advantages of CardioMap ™ CardioMap™ Images
(Dispersion Maps)
CardioMap requires less training to use and
analyze than EKGs
Healthy Heart
CardioMap is more sensitive than EKG’s; captures
low-level electrical signals that EKG’s don’t pick up
CardioMap can generate a 3D dispersion map of
the heart (see images) Moderately Diseased Heart
Physicians using CardioMap can give patients
actionable information about heart health years
in advance
Severely Diseased Heart
©2021 Odyssey Group International | OTC: ODYY 17Save-A-Life
Choking Rescue Device
©2021
In development, not commercially Odyssey Group International | OTC: ODYY
available 18Save-A-Life (SAL) is a patented, single-action, instantaneous,
handheld, mechanical, anti-choking device that creates a vacuum
chamber in the mouth to dislodge throat obstructions in a matter
of seconds without harm to the victim
In development, not commercially available
©2021 Odyssey Group International | OTC: ODYY 19Save-A-Life Device
• Proof of concept established In the US, Choking
• Prototypes developed by industry expert Results in
Tanaka Kapek Design Group
• Value extends to households, businesses, 100,000
schools, and public safety
Annual ER Visits and is the
• Global opportunity 3x of the U.S.
• Fast regulatory path via 510(k), no human 4th
trial needed
Leading cause of
unintentional injury death
©2021 Odyssey Group International | OTC: ODYY 20Advantages
Ready for Impeccable Competitive
Action Design Edge
• Device always charged and • Patented design depresses • Low-cost manufacturing
ready via rechargeable tongue, immobilizes palate design, including packaging
battery & resting cradle from reflex spasm and replaceable vacuum
tube and throat tubes
• Easy to use by adults and • Opens the air passage using
children; could also be self- replaceable tongue • Competing choking devices
administered depressor vacuum tube use a cumbersome mask
that needs to be placed over
• Controlled vacuum action the nose and mouth or could
lifts the lodged mass from possibly create too powerful
the larynx so it can be of a vacuum
ejected by reflexive
coughing
©2021 Odyssey Group International | OTC: ODYY 21Comparison
Table Save A Life Lifevac Dechoker
Heimlich
Maneuver
Easy to Use on others X
Easy to Use on self X X X
Safe for use on pregnant women X
Use on anyone X X
Vacuum pressure sensitive X X X
Clears tongue X X X
Rapid reuse on same patient
Rapid reuse on different patient X X
Low price X
Multiple Patents X X X
©2021 Odyssey Group International | OTC: ODYY 22Device Timelines 1Q22 2Q22 3Q22
Initiate Clinical Trial
CardioMap
510(k) Submission
Commercial Launch
Initiate Clinical Trial
Save-A-Life
510(k) Submission
Commercial Launch
Estimates only, pending funding and product development
©2021 Odyssey Group International | OTC: ODYY 23J. Michael Redmond,
Board Members
Chairman, CEO, and CFO
30 years experience leading Medical Device companies, commercialized several class II and Class III devices
Jake Van Landingham, Director
Jake is currently Executive VP of Drug Development. Jake holds a Ph.D. in Neuroscience.
John Gandolfo, Director
John has been CFO of several public and private medical device companies. He has raised over $300M in IPOs and
secondary offerings
Jerome (Jerry) Casey, Director
Jerry has 30 years experience leading commercial teams at Abbott Laboratories and recently as President of
Genzyme Diagnostics (Sekesui)
Jeff Conroy, Director
Jeff is currently the Chairman and CEO of Embody Inc and brings over 29 years experience in the medical industry
commercializing products and developing strategic alliances
Ricky Richardson
Ricky has over 30 years of experience as a global operations and quality leader in Medical devices. Mr. Richardson
has held senior positions at Baxter, Stryker and Danaher
©2021 Odyssey Group International | OTC: ODYY 24Summary
Issued Patents on Multiple Technologies
Phase 1 Human Trial Imminent for First of Kind
Concussion Treatment
Strong, Experienced Management and Board
Anticipate up-listing in 2021
©2021 Odyssey Group International | OTC: ODYY 25Developing and acquiring life-saving
medical products
Investor Presentation
July 2021
OTC: ODYY
©2021 Odyssey Group International | OTC: ODYY 26You can also read
